File card for Exelon makes unsubstantiated superiority claims

A professional file card for Novartis' Exelon makes unsubstantiated superiority claims, overstates the drug's efficacy, includes misleading risk presentations and recommends or suggests an unapproved use, says the FDA. It wants Novartis to submit a plan for circulating corrective materials.

You must be a registered member of MMM to post a comment.

Next Article in Legal/Regulatory


Did you miss January's Top 40 Healthcare Transformers issue? Read how these inventors, strategists, entrepreneurs and wonks are challenging, disrupting and otherwise transforming the healthcare business. And join us April 30 to honor them at the Transforming Healthcare Dinner. Click here.